PF-07038124在皮炎和斑块性牛皮患者的疗效和安全性:一项随机临床试验
Lawrence F Eichenfield1,2,3, Sanela Tarabar4, Seth Forman5
1Department of Dermatology, University of California, San Diego, School of Medicine.
JAMA dermatology
|December 20, 2023
概括
在2a期试验中,局部PF-07038124显著改善了亚托皮炎 (AD) 和斑块性牛皮的症状. 这种固酶4抑制剂在没有应用部位反应的情况下表现出卓越的疗效,提供了耐受良好的治疗选择.
科学领域:
- 皮肤病学和免疫学
- 炎症性皮肤疾病是一种炎症性皮肤疾病.
- 局部治疗的治疗方法.
背景情况:
- 亚托皮炎 (AD) 和斑块性牛皮是一种常见的炎症性皮肤疾病.
- 现有的局部治疗方法往往有局限性,包括应用部位反应.
- 需要新的,有效的局部疗法,改善安全性.
研究的目的:
- 为了评估PF-07038124的疗效和安全性,它是一种局部固酶4抑制剂.
- 评估其作为治疗轻度至中度无性皮炎和斑块性牛皮的潜力.
主要方法:
- 2a期,随机,双盲,载体控制的临床试验.
- 104名患有轻度至中度AD或斑块性牛皮的患者被随机分配 (1:1).
- 治疗涉及PF-07038124 (0.01%膏) 或载体,每天一次,持续6周.
- 主要终点:阿尔茨海默氏症的湿疹区域和严重性指数 (EASI) 和牛皮的牛皮区域和严重性指数 (PASI) 在第6周的百分比变化.
主要成果:
- PF-07038124在阿尔茨海默病的EASI评分中显示出显著更大的改善 (-74.9%对-35.5%,P <.001).
- PF-07038124在牛皮的PASI分数中显示出显著更大的改善 (-4.8比0.1,P<.001).
- 治疗出现的不良事件在两组之间是可比的;没有报告PF-07038124.4的应用部位反应.
结论:
- 局部PF-07038124耐受性良好,与载体相比,它表现出更高的疗效.
- 这项研究支持PF-07038124作为对轻度至中度AD和斑块牛皮的有前途的局部治疗方法.
- 其有利的安全性,特别是没有应用部位反应,是其关键优势.
更多相关视频
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.7K
02:28Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
416
相关概念视频
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).